Literature DB >> 11517930

Activation of progelatinase A by mammalian legumain, a recently discovered cysteine proteinase.

J M Chen1, M Fortunato, R A Stevens, A J Barrett.   

Abstract

The activation of progelatinase A to gelatinase A requires cleavage of an asparaginyl bond to form the N-terminus of the mature enzyme. We have asked whether the activation can be mediated by legumain, the recently discovered lysosomal cysteine proteinase that is specific for hydrolysis of asparaginyl bonds. Addition of purified legumain to the concentrated conditioned medium from HT1080 cell culture that contained both progelatinases A and B caused the conversion of the 72 kDa progelatinase A to the 62 kDa form. The progelatinase B in the medium was unaffected. Incubation of recombinant progelatinase A with legumain resulted in an almost instantaneous activation as judged by the fluorometric assay with a specific gelatinase A substrate, Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2. Legumain also activated progelatinase A when it was in complex with TIMP-2. Zymographic analysis and N-terminal sequencing revealed that legumain cleaved the 72 kDa progelatinase A at the bonds between Asn109-Tyr110 or Asn111-Phe112 to produce the 62 kDa mature enzyme, and that further cleavage at Asn430 also occurred to generate a 36 kDa active form. More 62 kDa gelatinase A was detected in cultures of C13 cells that over-expressed legumain than in those of the control HEK293 cells. We conclude that legumain is clearly capable of processing progelatinase A to the active enzyme in vitro and in cultured cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11517930     DOI: 10.1515/BC.2001.093

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  37 in total

1.  Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug.

Authors:  Yuan Liu; Krishna Mohan Bajjuri; Cheng Liu; Subhash C Sinha
Journal:  Mol Pharm       Date:  2011-11-22       Impact factor: 4.939

2.  Cross-talk between NADPH oxidase-PKCα-p(38)MAPK and NF-κB-MT1MMP in activating proMMP-2 by ET-1 in pulmonary artery smooth muscle cells.

Authors:  Jaganmay Sarkar; Animesh Chowdhury; Tapati Chakraborti; Sajal Chakraborti
Journal:  Mol Cell Biochem       Date:  2016-02-24       Impact factor: 3.396

3.  Thrombin-dependent MMP-2 activity is regulated by heparan sulfate.

Authors:  Bon-Hun Koo; Jung Ho Han; Young Il Yeom; Doo-Sik Kim
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

4.  Structural analysis of asparaginyl endopeptidase reveals the activation mechanism and a reversible intermediate maturation stage.

Authors:  Lixia Zhao; Tian Hua; Christopher Crowley; Heng Ru; Xiangmin Ni; Neil Shaw; Lianying Jiao; Wei Ding; Lu Qu; Li-Wei Hung; Wei Huang; Lei Liu; Keqiang Ye; Songying Ouyang; Genhong Cheng; Zhi-Jie Liu
Journal:  Cell Res       Date:  2014-01-10       Impact factor: 25.617

5.  Counter Selection Substrate Library Strategy for Developing Specific Protease Substrates and Probes.

Authors:  Marcin Poreba; Rigmor Solberg; Wioletta Rut; Ngoc Nguyen Lunde; Paulina Kasperkiewicz; Scott J Snipas; Marko Mihelic; Dusan Turk; Boris Turk; Guy S Salvesen; Marcin Drag
Journal:  Cell Chem Biol       Date:  2016-07-28       Impact factor: 8.116

6.  Blockade of Asparagine Endopeptidase Inhibits Cancer Metastasis.

Authors:  Qi Qi; Obiamaka Obianyo; Yuhong Du; Haian Fu; Shiyong Li; Keqiang Ye
Journal:  J Med Chem       Date:  2017-08-18       Impact factor: 7.446

7.  The asparaginyl endopeptidase legumain after experimental stroke.

Authors:  Taku Ishizaki; Agnes Erickson; Enida Kuric; Mehrdad Shamloo; Ikuko Hara-Nishimura; Ana Rita Lourenço Inácio; Tadeusz Wieloch; Karsten Ruscher
Journal:  J Cereb Blood Flow Metab       Date:  2010-03-17       Impact factor: 6.200

8.  Effects of legumain as a potential prognostic factor on gastric cancers.

Authors:  Na Li; Qiaoling Liu; Qi Su; Chongyang Wei; Bin Lan; Jianyong Wang; Guoqing Bao; Fei Yan; Ying Yu; Baowei Peng; Ju Qiu; Xiangming Yan; Sheng Zhang; Fang Guo
Journal:  Med Oncol       Date:  2013-06-06       Impact factor: 3.064

9.  Chemically Programmed Bispecific Antibody Targeting Legumain Protease and αvβ3 Integrin Mediates Strong Antitumor Effects.

Authors:  Yuan Liu; Rajib K Goswami; Cheng Liu; Subhash C Sinha
Journal:  Mol Pharm       Date:  2015-06-09       Impact factor: 4.939

10.  Cystatin E/M suppresses legumain activity and invasion of human melanoma.

Authors:  Jon J Briggs; Mads H Haugen; Harald T Johansen; Adam I Riker; Magnus Abrahamson; Øystein Fodstad; Gunhild M Maelandsmo; Rigmor Solberg
Journal:  BMC Cancer       Date:  2010-01-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.